Literature DB >> 7523715

Basic fibroblast growth factor (FGF-2) in renal cell carcinoma, which is indistinguishable from that in normal kidney, is involved in renal cell carcinoma growth.

N Emoto1, O Isozaki, E Ohmura, F Ito, T Tsushima, K Shizume, H Demura, H Toma.   

Abstract

To investigate the role of basic fibroblast growth factor (FGF) in renal cell carcinoma growth, we have analyzed the expression of mRNA of basic FGF. In 7 of 15 cases, basic FGF mRNA level in renal cell carcinoma tissues was higher than that in corresponding normal tissues. However, the tumor-to-normal ratios of expression levels are chiefly less than 2.0 and, in 5 cases, are even less than 1.0. Furthermore, there was no correlation between the ratio and the clinical stage. In protein analysis, we could not find any difference between basic FGF extracted from renal cell carcinomas and that from normal kidney tissues in bioactivity, immunoreactivity, molecular weight and affinity to heparin. On the other hand, anti-basic FGF monoclonal antibody inhibited the growth of a renal cell carcinoma cell line, VMRC-RCW, and this inhibition was reversed by an extraphysiological amount of exogenous basic FGF (100 ng./ml.). These results suggest that basic FGF itself may have no pivotal role in renal cell carcinoma etiology but is involved in the growth of renal cell carcinomas in an autocrine manner.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523715     DOI: 10.1016/s0022-5347(17)32492-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.

Authors:  M Horstmann; A S Merseburger; E von der Heyde; J Serth; G Wegener; M Mengel; G Feil; J Hennenlotter; U Nagele; A Anastasiadis; C Bokemeyer; A Stenzl; M Kuczyk
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

Review 2.  Perspectives in drug development for metastatic renal cell cancer.

Authors:  Bristi Basu; Tim Eisen
Journal:  Target Oncol       Date:  2010-08-06       Impact factor: 4.493

Review 3.  Update on targeted therapies for clear cell renal cell carcinoma.

Authors:  Eric A Singer; Gopal N Gupta; Ramaprasad Srinivasan
Journal:  Curr Opin Oncol       Date:  2011-05       Impact factor: 3.645

4.  A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Authors:  Martin H Voss; Cinta Hierro; Rebecca S Heist; James M Cleary; Funda Meric-Bernstam; Josep Tabernero; Filip Janku; Leena Gandhi; A John Iafrate; Darrell R Borger; Nobuya Ishii; Youyou Hu; Yulia Kirpicheva; Valerie Nicolas-Metral; Anna Pokorska-Bocci; Anne Vaslin Chessex; Claudio Zanna; Keith T Flaherty; Jose Baselga
Journal:  Clin Cancer Res       Date:  2019-02-11       Impact factor: 13.801

Review 5.  Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?

Authors:  Alejandro R Chade; Nicholas Stewart
Journal:  J Am Soc Hypertens       Date:  2013-02-19

Review 6.  Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.850

7.  Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance.

Authors:  C Yiangou; J J Gomm; R C Coope; M Law; Y A Luqmani; S Shousha; R C Coombes; C L Johnston
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Comparative STAT3-Regulated Gene Expression Profile in Renal Cell Carcinoma Subtypes.

Authors:  Rebekah L Robinson; Ashok Sharma; Shan Bai; Saleh Heneidi; Tae Jin Lee; Sai Karthik Kodeboyina; Nikhil Patel; Shruti Sharma
Journal:  Front Oncol       Date:  2019-02-26       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.